What is it about?
This article is an editorial for a series I co-ordinated for Endocrine-Related Cancer on ubiquitin (and ubiquitin-like proteins) and cancer. It introduces four review articles in this series, including our own (Cole et al 2015) on Histone H2B monoubiquitination (a master regulator of transcription with connection to cancer); Johnson on the ubiquitin proteasome and therapeutic opportunties for solid tumours; Pfoh et al on deubiquitinases (DUBs) and cancer therapy; and, Abidi & Xirodimis on NEDDYLATION and NEDD8 inhibitors.
Featured Image
Why is it important?
This editorial introduces Endocrine-Related Cancer's Feb 2015 thematic series of ubiquitin and ubiquitin-like proteins in cancer, with special focus on opportunities for therapy in solid tumours. You just need to decide which review article to read first in this exciting area !!
Perspectives
It was a privilege to co-ordinate this thematic series on ubiquitin and ubiquitin-like proteins in cancer. This is an exciting area and one in which my own laboratory is placing considerable research efforts.
Professor Deborah J Marsh
University of Sydney
Read the Original
This page is a summary of: Networks regulating ubiquitin and ubiquitin-like proteins promise new therapeutic targets, December 2014, Bioscientifica,
DOI: 10.1530/erc-14-0585.
You can read the full text:
Contributors
The following have contributed to this page
